Moreover, K–M analysis conducted on a tamoxifen-treated luminal A BC cohort of patients, with long-term follow-up (180 months), showed an even increased protection against recurrence and distant metastasis when both FoxO3a and integrin α5 are co-expressed (Figure 5c,d) compared to FoxO3a alone (Appendix D). Here, FOXO3 is linked to breast cancer.